Novo Nordisk has launched the first GLP-1 weight-loss pill in the US.
The once-daily Wegovy pill costs far less than injectable versions.
Self-paying patients can buy the starting dose for $149 per month.
Higher doses will rise to between $199 and $299 monthly later this year.
The pill offers a needle-free alternative and broader patient appeal.
US approval came just before Christmas, with rollout now under way nationwide.
Novo hopes the pill will regain market share after recent profit warnings.
Shares rose on launch news despite intense competition from Eli Lilly.
Eli Lilly is developing a rival obesity pill with capped pricing plans.
UK regulators are reviewing Wegovy pill approval later this year.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Keep Reading
Add A Comment
The Mundo Post delivers powerful stories, breaking news, sports, and culture—bringing bold perspectives and timely updates to keep readers informed, inspired, and connected worldwide.
We’re social. Connect with us:

